CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX.

Wenting Jia,Caiping Ren,Lei Wang,Bin Zhu,Wei Jia,Menghui Gao,Fei Zeng,Liang Zeng,Xiaomeng Xia,Xiaobing Zhang,Ting Fu,Shasha Li,Can Du,Xingjun Jiang,Yuxiang Chen,Weihong Tan,Zilong Zhao,Weidong Liu

DOI: https://doi.org/10.18632/oncotarget.10530

2016-01-01

Oncotarget

Abstract:Nasopharyngeal carcinoma (NPC) is one of the most prevailing cancers in southern China and southern Asia. Because of the nonspecific symptoms and lack of effective biomarker, most patients are diagnosed at advanced stages, resulting in poor 5-year survival rate. To identify a novel NPC biomarker facilitating early detection and effective therapy of NPC, a two-step strategy consisting of cancer cell-Systematic Evolution of Ligands by EXponential enrichment (cell-SELEX) procedure and aptamer-based purification approach was developed. Using cell-SELEX procedure, four aptamers (S3, S5, S12 and S27) differentiating the molecular differences between NPC cells and NP cells were successfully screened. Then, using aptamer-based protein purification, membrane protein CD109 was identified as the target of aptamer S3. CD109 protein was further identified to be over-expressed in NPC cell lines and clinic tissues, but not or low in NP cell line and clinic NP tissues, detected by western blot and immunohistochemistry experiments. Our study demonstrated that CD109 identified by cell-SELEX and aptamer-based purification strategy might be used as a potential NPC biomarker for early diagnosis and targeted therapy.